ClinicalTrials.gg

Program

sapanisertib

Also written as “Sapanisertib”, “MLN0128” and “TAK-128”.

Its studies are mostly in Breast Neoplasms · Endometrial Neoplasms · Diabetic Neuropathies · Carcinoma, Non-Small-Cell Lung · Clear-cell metastatic renal cell carcinoma, led by 3 companies.

Furthest: phase 2, since Sep 27, 200514 company-led studies, 2 open or runningNext primary completion: Sep 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda80 open or runningphase 2since Sep 27, 2005Sep 27, 2005none ahead
Calithera Biosciences30 open or runningphase 2since Apr 28, 2016Jul 21, 2014none ahead
Faeth Therapeutics32 open or runningphase 2since Feb 7, 2022Feb 7, 2022Sep 2028phase 2 · NCT06463028

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 27, 2005First study: phase 2 study in Diabetic NeuropathiesNew to TakedaTakeda · NCT00229437 · 343 enrolled · United States, Canada
  2. Sep 17, 2008Phase 2 study in Diabetic NeuropathiesTakeda · NCT00756041 · 221 enrolled
  3. Jan 27, 2010Phase 1 study in Advanced Solid MalignanciesTakeda · NCT01058707 · 198 enrolled · United States, Spain
  4. May 5, 2010Phase 1 study in Multiple MyelomaTakeda · NCT01118689 · 39 enrolled · United States
  5. Feb 21, 2011Phase 1 study in Hematologic NeoplasmsTakeda · NCT01351350 · 68 enrolled · United States
  6. Jul 10, 2013Phase 1 study in Advanced Nonhematologic MalignanciesTakeda · NCT01899053 · 101 enrolled · United States, Spain, United Kingdom
  7. Jul 21, 2014Calithera Biosciences's first study: phase 1 study in Advanced Solid TumorsNew to Calithera BiosciencesCalithera Biosciences · NCT02197572 · 44 enrolled · United States
  8. Mar 25, 20162 phase 2 studiesTakeda · NCT02724020, NCT02725268
  9. Apr 28, 2016Phase 2 study in Breast NeoplasmsCalithera Biosciences · NCT02756364 · 141 enrolled · United States, Spain
  10. Dec 7, 2017Phase 1 study in Advanced Nonhematological NeoplasmsCalithera Biosciences · NCT03370302 · 28 enrolled · Japan, Korea, Republic of, Taiwan
  11. Feb 7, 2022Faeth Therapeutics's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Faeth TherapeuticsFaeth Therapeutics · NCT05275673 · 7 enrolled · United States
  12. Jun 11, 2024Phase 2 study in Endometrial NeoplasmsFaeth Therapeutics · NCT06463028 · 40 planned · United States
  13. Apr 17, 2026Phase 2 study in Breast NeoplasmsFaeth Therapeutics · NCT07558733 · 32 planned · United States

Ahead

  1. Sep 2028Primary completion: phase 2 study in Endometrial NeoplasmsFaeth Therapeutics · NCT06463028
  2. May 2029Primary completion: phase 2 study in Breast NeoplasmsFaeth Therapeutics · NCT07558733

TargetBeta

MTOR →read by rule
“Serine/threonine-protein kinase mTOR inhibitor”ChEMBL 37, by rule

Other programs on MTOR

ProgramCompanyFurthest phaseStudies
SirolimusPfizerphase 466
gedatolisibrulePfizerphase 39
PI3K/mTOR Kinase Inhibitor WXFL10030390ruleshanghai-jiatan-pharmatech-co-ltdphase 36

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07558733Breast Neoplasms · United States2RecruitingFaeth TherapeuticsMay 202932
NCT06463028Endometrial Neoplasms · United States2RecruitingFaeth TherapeuticsSep 202840
NCT05275673Carcinoma, Non-Small-Cell Lung · United States2TerminatedFaeth TherapeuticsJan 24, 20237
NCT03370302Advanced Nonhematological Neoplasms · Japan, Korea, Republic of, Taiwan1TerminatedCalithera BiosciencesAug 28, 201928
NCT02756364Breast Neoplasms · United States, Spain2CompletedCalithera BiosciencesNov 25, 2019141
NCT02725268Endometrial Neoplasms · United States, Australia, Belgium and more2CompletedTakedaJul 2, 2019241
NCT02724020Clear-cell metastatic renal cell carcinoma · United States, Canada, Czechia and more2CompletedTakedaFeb 3, 202096
NCT02197572Advanced Solid Tumors · United States1CompletedCalithera BiosciencesJun 10, 201644
NCT01899053Advanced Nonhematologic Malignancies · United States, Spain, United Kingdom1CompletedTakedaJan 31, 2017101
NCT01351350Hematologic Neoplasms · United States1CompletedTakedaSep 15, 201768
NCT01118689Multiple Myeloma · United States1CompletedTakedaMay 201339
NCT01058707Advanced Solid Malignancies · United States, Spain1CompletedTakedaFeb 7, 2019198
NCT00756041Diabetic Neuropathies2TerminatedTakedaSep 2006221
NCT00229437Diabetic Neuropathies · United States, Canada2CompletedTakedaMay 2006343

How it is read

Names in the registry

  • “Sapanisertib”, 5 entries
  • “MLN0128”, 4 entries
  • “TAK-128”, 4 entries
  • “TAK-228”, 2 entries
  • “sapanisertib”, 1 entry

Codes read as this program: TAK128.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.